Recruiting Bladder Cancer Studies in Indianapolis
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3...
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the safety and preliminary efficacy of s...
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
This Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle inv...
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), th...
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Patients with MIBC will receive 3 cycles (C1-C3) of induction enfortumab vedotin plus pembrolizumab followed by restaging including MRI of the bladder, urine cytology, and cystoscopy with TURBT of any...
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducte...
About Bladder Cancer Clinical Trials in Indianapolis
Bladder cancer occurs in the tissues of the bladder and is one of the most common cancers. It has a high recurrence rate, requiring ongoing monitoring. Treatments include surgery, intravesical therapy, chemotherapy, and immunotherapy.
There are currently 6 bladder cancer clinical trials recruiting participants in Indianapolis, IN. These studies are seeking a combined 562 participants. Research is being sponsored by Ferring Pharmaceuticals, Merck Sharp & Dohme LLC, UroGen Pharma Ltd. and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Bladder Cancer Clinical Trials in Indianapolis — FAQ
Are there bladder cancer clinical trials in Indianapolis?
Yes, there are 6 bladder cancer clinical trials currently recruiting in Indianapolis, IN. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Indianapolis?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Indianapolis research site will contact you about next steps.
Are clinical trials in Indianapolis free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Indianapolis studies also compensate for your time and travel.
What bladder cancer treatments are being tested?
The 6 active trials in Indianapolis are testing new therapies including novel drugs, biologics, and treatment approaches for bladder cancer.
Data updated March 2, 2026 from ClinicalTrials.gov